SOMATIC GENE VARIANTS IN UNRESECTABLE CUTANEOUS MELANOMA CELLS AND DETECTION OF PHARMACOGENOMIC MARKERS: INFLUENCE ON STRATEGY OF EFFECTIVE CANCER TREATMENT

Our study presents the fi st comprehensive analysis of somatic mutations and pharmacogenomic markers in unresectable cutaneous melanoma tissue samples from Ukrainian patients. We found that while common somatic variants generally align with global trends, the mutational landscape in this cohort presents several unique features: a high KRAS mutation rate and its apparent stage-specifi prevalence, and a high FLT3 mutation rate, predominantly in stage IV tumors. further validation on a larger number of samples, as well as more exhaustive analysis employ- ing alternative methods, is necessary to substantiate these fi dings and to facilitate more effective melanoma treatment.